Pfizer resumes hemophilia study after nearly yearlong pause
![Photo: Peter Nicholls/REUTERS / X03508](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14435852.ece/ALTERNATES/schema-16_9/doc7mwvcvax2t1ahynnch.jpg)
After a halt of nearly a full year, Pfizer and partner Sangamo Therapeutics have chosen to resume a phase III study of drug candidate giroctocogene fitelparvovec, a potential gene therapy for moderate-to-severe hemophilia A, Pfizer announces in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
FDA speeds up assessment of Sobi-Sanofi hemophilia drug
For subscribers